Efficacy and Safety of PEG-Intron Plus Rebetol in Subjects With Chronic Hepatitis C Genotype 1 Non Responder to Pegasys.
Phase of Trial: Phase III
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms ESPECIAL
- Sponsors Schering-Plough
- 07 Nov 2014 Planned number of patients changed from 117 to 200, according to European Clinical Trials Database record.
- 13 Oct 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 11 Aug 2009 Planned number of patients changed from 200 to 117 as reported by ClinicalTrials.gov.